INTRODUCTION
Exposure to environmental teratogenic pollutants is a major threat to embryonic development. In humans, among the population presenting birth defects, about 10%-15% of these anomalies are due to exposure of pregnant women to environmental teratogenic pollutants (Gilbert-Barness, 2010). Among these developmental defects, craniofacial malformations represent a third of the defects observed (Dixon et al., 2011) . It is postulated that most teratogens interfere with genetic programs regulating developmental processes (Dixon et al., 2011) . Among environmental pollutants, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), commonly known as dioxin, is a recognized potent teratogen (Yonemoto, 2000) . During historical events such as the American Vietnam War or the Seveso incident, populations were exposed to high doses of TCDD (Mocarelli, 2001; Stellman et al., 2003) . It was suggested that the spreading of TCDD led to an increase in congenital defects, but rigorous epidemiologic study establishing the link with TCDD exposure are lacking. Nevertheless, TCDD exposure has been associated with developmental alterations, including impaired psychomotor functions and cognition, as well as reproductive and developmental defects (White and Birnbaum, 2009 ). Furthermore, mouse embryos exposed to TCDD present with hydronephrosis, thymic hypoplasia, craniofacial defects such as cleft palate, reduced weight, and lethality at high doses (Courtney and Moore, 1971; King-Heiden et al., 2012; Kransler et al., 2007; Moore et al., 1973; Pratt et al., 1984; Yamada et al., 2006; Yonemoto, 2000) .
The aryl hydrocarbon receptor (AHR) has been identified as the receptor to TCDD (Fernandez-Salguero et al., 1996; Hankinson, 1995) , suggesting this signaling pathway could be involved in TCDD-mediated teratogenesis. While the etiology of TCDDinduced developmental defects remains unclear and studies linking TCDD exposure and oral cleft in human are lacking, palatal shelves from human, rat, and mouse display similar response to TCDD exposure in vitro (Abbott et al., 1999a) , which suggests that human exposure to TCDD may be associated with oral clefts.
In vertebrates, the face mainly derives from the neural crest (NC), a transient structure that arises at the dorsal tip of the closing neural tube (Knecht and Bronner-Fraser, 2002) . Cells from the neuroepithelium undergo an epithelial-mesenchymal transition prior to migrating to various regions of the embryo. Depending on their location along the anterior-posterior axis, these cells populate different structures and give rise to a large variety of cell types (Le Douarin et al., 2004) . In the most rostral part of the embryo, cranial NC cells (CNCC) migrate ventro-laterally to colonize facial prominences (Birgbauer et al., 1995; Lumsden et al., 1991; Osumi-Yamashita et al., 1994; Serbedzija et al., 1992) , where they participate in the formation of craniofacial bones, cartilage, connective tissue, neurons, and glial cells (Couly et al., 1993; Dupin and Sommer, 2012; Knecht and Bronner-Fraser, 2002; Kö ntges and Lumsden, 1996; Noden and Trainor, 2005) . Craniofacial malformations are generally linked to anomalies in CNCC development, part of them being due to teratogen exposure. Despite the identification of gene regulatory networks (GRNs) underpinning CNCC development (Betancur et al., 2010) , little is known about how environmental pollutants interfere with these genetic networks during craniofacial development.
Central to these GRNs are genes coding for the paralogous paired-box transcription factors PAX3 and PAX7. These transcriptional regulators play a key role in the integration of inputs during NC induction and in controlling the specification of NC derivatives (Basch et al., 2006; Betancur et al., 2010; Minchin and Hughes, 2008; Monsoro-Burq et al., 2005; Sato et al., 2005) . Although Pax3 and Pax7 function during early NC development is highly conserved among vertebrates (Betancur et al., 2010) , their function during craniofacial formation is not understood.
Here, we show that mutant mice with impaired Pax3 and Pax7 function display severe facial morphogenesis defects. Using a large-scale transcriptomic approach, we identified the AHR signaling pathway as specifically upregulated during craniofacial development of Pax3/7 deficient mice, leading to precocious growth arrest in the cranial NC lineage. We further show that blocking AHR signaling rescues facial growth and closure in mice with impaired Pax3/7 function, while exposure to AHR agonists such as TCDD leads to similar defects in embryos Are Essential for Facial Development (A) Histological transverse sections across the head regions of E11.5 Pax3 GFP/+ ; Pax7 LacZ/+ , Pax3 GFP/GFP ; Pax7 LacZ/LacZ , and Pax3 Pax3-ERD/GFP embryos at two distinct levels of the nasal process, as indicated by black lines in the embryo scheme. Hematoxylin eosin (H/E); lateral nasal process (LNP); medial nasal process (MNP); nasal pit (NP); neuroepithelium (NE); olfactory epithelium (OE); and eye (E). Scale bar, 500 mm. (B) Bright field and GFP expression (top and middle panels, facial views) of E13.5 embryos of Pax3 GFP/+ ; Pax7 LacZ/+ , Pax3 GFP/GFP ; Pax7 LacZ/LacZ , and Pax3 Pax3-ERD/GFP embryos. Arrowheads represent normally formed nasal processes. White stars indicate rudimentary nasal processes. Bottom panels show histological transverse sections through the nasal processes of these embryos, as indicated by the black line in the embryo scheme. Black stars indicate divided nasal septum. Scale bars, 500 mm. (C) GFP expression in E9.5 Pax3 GFP/+ ; Pax7 LacZ/+ , Pax3 GFP/GFP ; Pax7 LacZ/LacZ , and Pax3 Pax3-ERD/GFP embryos (lateral views). Arrowheads indicate the CNCC migrating into the facial prominences. Scale bar, 200 mm.
with reduced PAX3/7 activity, genetically linking Pax3/7 with Ahr. Our data therefore demonstrate that important developmental genes play a key function to preserve the developing face from AHR/ TCDD-mediated teratogenesis.
RESULTS

Essential Role of Pax3 and Pax7 during Craniofacial Development
Using mouse genetic models, we first examined the dynamics of Pax3 and Pax7 expression profiles during craniofacial development. As in other vertebrates (Nelms and Labosky, 2010) , Pax3 expression is detected within the anterior neural plate border prior to neural tube closure at embryonic day (E)8.5 ( Figure S1A ). PAX3 expression co-localizes with the NCC marker SOX9 (Nelms and Labosky, 2010; Figure S1B) and persists in several CNCC-derived tissues such as the frontonasal mass (FNM) and the medial and lateral nasal processes (MNP and LNP; Figure S1C ). Of note, Pax7 expression is restricted within Pax3 domain; first observed in the FNM and the LNP, and later maintained in the LNP at E10.5 and E11.5 (Figures S1C and S1D).
We next analyzed facial morphology in two distinct models with altered PAX3 and PAX7 functions ( Figures 1A and 1B ). While Pax3 is required for NC induction in the sacral, trunk, and vagal regions (Li et al., 1999; Van Ho et al., 2011) , cranial NC induction occurs in our genetic models. However, a strong frontonasal dysplasia phenotype with a fully penetrant frontal cleft was observed in both Pax3 GFP/GFP ; Pax7 LacZ/LacZ double mutant and Pax3 Pax3-ERD/GFP mutant embryos ( Figures 1A, 1B , and S2A). In the latter, cells in the Pax3 positive lineage expressed a potent dominant-negative form of Pax3 (Pax3-ERD), which alters both PAX3 and PAX7 function (Bajard et al., 2006) . This phenotype contrasted with the medial fusion of the nasal processes observed in wild-type (WT) embryos and other compound Pax3/Pax7 mutants ( Figure S2B ), supporting the notion that both proteins are required for facial development in mice. In Pax3; Pax7 double mutant embryos, the phenotype was more severe than in Pax3 Pax3-ERD/GFP embryos, where the medial and lateral nasal swellings were rudimentary and failed to fuse resulting to a frontonasal cleft, whereas the maxillary and mandibular prominences were less affected ( Figures 1A, 1B , and S2A). Histological analyses at E11.5 and E13.5 revealed that the nasal process of both genetic models was severely diminished and the nasal septum bifurcated ( Figures 1A and 1B ).
Since CNCC reached the facial prominences and early specification is not affected in our genetic models , we next assessed whether craniofacial defects observed in Pax3 Pax3-ERD/GFP and Pax3; Pax7 double mutant embryos were due to increased cell death of CNCC. Strikingly, we observed an increased proportion of apoptotic CNCC when both Pax3 and Pax7 were missing ( Figure 2D ). Furthermore, we were unable to detect any cell co-expressing GFP (PAX3) and b-galactosidase (PAX7) at E10.5 or E11.5 (data not shown), suggesting that the PAX3 + /PAX7 + cell population is lost in double mutant embryos, precluding further analysis in this genetic model.
In contrast, cell death was not increased in the CNCC of Pax3 Pax3-ERD/GFP embryos ( Figure 2D ). Thus, we tested whether the frontal cleft face phenotype observed in Pax3 Pax3-ERD/GFP could be a consequence of tissue misspecification. We observed impaired expression of Msx1 in the MNP and LNP ( Figure 2E ) associated with reduced expression of Pax7 and Pax9 in the LNP ( Figure S3A ), suggesting a proliferation defect in the nasal processes of Pax3 Pax3-ERD/GFP embryos (Bhatt et al., 2013; Houzelstein et al., 1997; Nelms and Labosky, 2010) . In addition, Dlx2 expression in nasal pits was barely detectable ( Figure 2E ), implying patterning defects of the nasal process in Pax3 Pax3-ERD/GFP embryos (McKeown et al., 2005; Thomas et al., 2000) . As confirmed by skeletal staining at E17.5, Pax3 Pax3-ERD/GFP fetuses primarily presented with defects in the premaxilla and the palate bones ( Figure S3B ). The primary palate was almost completely absent, while the secondary palate was formed, but divided in two halves in Pax3 Pax3-ERD/GFP embryos ( Figures 2F and S3B ).
Collectively, these data demonstrate that Pax3 and Pax7 are essential in regulating morphogenesis, survival, patterning, and specification of the frontonasal structures during facial development.
Upregulation of AHR Signaling Pathway Expression Is
Associated with Impaired Pax3/7 Function In order to gain insight into the molecular mechanism by which Pax3 and Pax7 regulate craniofacial development, we performed a microarray screen to compare the transcriptomes of the facial prominences of Pax3 Pax3-ERD/GFP mutant and Pax3 GFP/+ embryos at E11.5 ( Figure 3A ). We identified 76 upregulated (Table S1 ) and 44 downregulated (Table S2 ) genes in cells with impaired Pax3/7 function compared to the control ( Figure 3A ). Among the deregulated genes, the most highly represented were components of the AHR signaling pathway that were upregulated in our screen, suggesting a strong activation of this signaling pathway in Pax3 Pax3-ERD/GFP embryos.
Transcripts levels for Ahr and its direct target genes, including Aldh1a3, a gene coding for an enzyme involved in retinoic acid production and nasal process development (Dupé et al., 2003; Hankinson, 1995) and p21 (Cdkn1a, cyclin-dependent kinase inhibitor 1A), a mediator of cell-cycle exit and growth arrest (Barnes-Ellerbe et al., 2004; Besson et al., 2008) , were higher in Pax3 Pax3-ERD/GFP CNCC ( Figure 3B ). Consistently, we detected a specific upregulation of AHR protein in the nasal process mesenchyme and epithelium in both E10.5 and E11.5 Pax3 Pax3-ERD/GFP embryos compared to control (Figures 3C and S4) . In situ hybridization for Aldh1a3 transcripts revealed that its expression in the nasal process was shifted to more anterior and medial positions within this tissue ( Figure 3D ), reinforcing the notion that AHR signaling activity domain is increased when the function of PAX3/7 is impaired. Furthermore, in the frontonasal ectoderm, Aldh1a3 was previously shown to regulate Fgf8 expression, a mediator of CNCC growth in the underlying mesenchyme (Dupé et al., 2003; Hu et al., 2003) . Consistent with this, expression of Fgf8 was lost in the nasal epithelium of (E) Aldh1a3 and p21 relative expression assayed by RT-qPCR in CNCC from E10.5 WT embryos, exposed to TCDD or carrier as indicated. Error bars represent the SD.
Pax3 Pax3-ERD/GFP embryos ( Figure 3D ), suggesting a decreased proliferation of the underlying mesenchymal CNCC that could explain the smaller nasal prominence phenotype. In addition, CNCC isolated from facial prominences exposed to TCDD, specifically induced Aldh1a3 and p21 expression ( Figure 3E ), demonstrating the responsiveness of AHR signaling to environmental pollutants in this tissue.
Impaired Pax3/7 Function Leads to CNCC Growth Arrest and Frontal Cleft Face
Migration of the CNCC takes place in Pax3 Pax3-ERD/GFP embryos ( Figure 1C ), since the number of GFP + cells was essentially the same in Pax3 Pax3-ERD/GFP and control embryos at E9.5 ( Figure 4A ). However, from E10.5 onward, the number of GFP + cells within the frontonasal region was decreased by 30% in Pax3 Pax3-ERD/GFP embryos compared to control ( Figure 4A ). Moreover, by E11.5 the proportion of GFP + fluorescenceactivated cell sorting (FACS)-sorted cells over the total number of cells was severely diminished by 34%, in Pax3 Pax3-ERD/GFP embryos compared to the control ( Figures 4B and 4C ). This decrease in the PAX3 + /PAX7 + population correlated with a decline in the number of cycling cells in this population ( Figures  4D and 4F) , which explains the overall reduction of nasal process size, leading to a frontal cleft face.
As we found a marked upregulation of the growth arrest gene p21 in Pax3 Pax3-ERD/GFP embryos, we hypothesized that p21 induction might lead to growth failure of the nasal process, resulting in the frontal cleft face phenotype. Immunostaining for p21 and PAX7 demonstrated that 43% of the cells had exited the cell cycle in Pax3 Pax3-ERD/GFP embryos, while only 26% of the cells normally did so at E10.5 (Figures 4E and 4G) . This increased cell-cycle exit was also seen at E11.5 ( Figure 4G ). In addition, this growth arrest was associated with a decrease in the CNCC progenitor pool, as shown by analysis of AP2a and SOX9 expression ( Figures 4H and 4I ). Together these results suggest that during facial prominences growth, upregulation of AHR signaling pathway in CNCC drives these cells out of the cell cycle. Hence, this precocious cellcycle exit generates reduced craniofacial prominences unable to fuse together, resulting in the formation of a frontal cleft face. Pax3/7-Mediated Regulation of AHR Signaling Allows CNCC Growth during Craniofacial Development In order to demonstrate that upregulation of AHR signaling leads to the morphological defects observed in Pax3 Pax3-ERD/GFP embryos, we treated control and mutant embryos with a-naphthoflavone, an AHR antagonist (Jang et al., 2007) . Treatments were performed by daily gavages administrated from E8.5 to E11.5. Strikingly, a considerable proportion (39%) of treated Pax3 Pax3-ERD/GFP embryos exhibited a rescue of the frontal cleft face at E13.5 compared to the DMSOtreated Pax3 Pax3-ERD/GFP embryos, which all display a frontal cleft face ( Figures 5A  and 5C ). Histological analysis of the rescued embryos revealed that the nasal septum was fused in its medial part (Figure 5A ). In addition, we observed that AHR inhibition was sufficient to rescue primary palate formation ( Figure 5B ). Moreover, as the alignment of the prominent rugae suggested, the fusion of the secondary palate appeared to be rescued, but delayed in time when compared with DMSO-treated Pax3 Pax3-ERD/GFP embryos, which present with a bifurcated secondary palate ( Figure 5B ).
Following inhibition of AHR signaling with a-naphthoflavone, the number of cycling PAX3 + /PAX7 + cells in both control and mutant embryos reached a similar level as in the DMSO-treated Pax3 GFP/+ control embryos ( Figure 5D ). Hence, inhibition of AHR signaling in Pax3 Pax3-ERD/GFP embryos was sufficient to rescue the proportion of proliferating cells in the PAX3 + /PAX7 + population.
To demonstrate that the rescue of the number of cycling CNCC was due to the inhibition of AHR signaling, we quantified the expression of p21 in these embryos. As anticipated, in nearly half of a-naphthoflavone-treated Pax3 Pax3-ERD/GFP embryos the expression level of p21 within the facial prominences reached similar levels compared to that observed in DMSO-treated Pax3 GFP/+ control embryos ( Figure 5E ), demonstrating that the specific inhibition of AHR signaling was sufficient to rescue the number of cycling CNCC in the facial prominences of these embryos.
We also tested b-naphthoflavone, an AHR agonist (Swanson and Perdew, 1993) . Strikingly, nearly all b-naphthoflavone-treated Pax3 GFP/GFP or Pax3 Pax3-ERD/GFP mutant embryos presented with an early lethality by E13.5. By contrast, WT and Pax3 GFP/+ Figure 5 . Genetic Interaction between Pax3 and AHR Signaling Is Essential for Normal Craniofacial Development embryos all developed normally (data not shown). The cause of death was not determined, but this further demonstrates a strong genetic link between Pax3/Pax7 and AHR signaling during development.
Altogether, our results demonstrate that during facial morphogenesis PAX3 and PAX7 act by regulating CNCC growth through the action of AHR signaling.
Pax3 and Pax7 Play a Safeguard Function against TCDD-Induced Craniofacial Defects
To further establish the link between Pax3/7 function and AHR signaling during craniofacial development, we speculated that they act by restricting the input of AHR signaling to specific locations in the facial prominences. We therefore hypothesized that reducing PAX3/7 activity in embryos exposed to TCDD should lead to facial defects. Accordingly, we used TCDD to stimulate AHR signaling in a Pax3-null context. To this end, we intercrossed Pax3 GFP/+ mice and treated the pregnant females with a low dose of TCDD. As expected, p21 expression was significantly upregulated in both TCDD-treated Pax3 GFP/+ and Pax3 GFP/GFP facial prominences ( Figure 6A ), confirming that AHR signaling was activated. Importantly, WT and Pax3 GFP/+ control embryos were normally formed. Yet, while all vehicle-treated control Pax3 GFP/GFP mutant embryos displayed a normal craniofacial phenotype, 56% of the TCDD-treated Pax3 GFP/GFP mutant embryos presented with a frontal cleft face phenotype (Figures 6B  and 6C ). This phenotype is reminiscent to the one observed in Pax3 Pax3-ERD/GFP embryos ( Figure 1B) and confirms that when PAX3 function is impaired, activating AHR signaling is sufficient to generate craniofacial defects.
Collectively, our results reveal an unexpected safeguard function for PAX3/7 during face morphogenesis, whereby they restrict AHR signaling input in order to allow the correct growth and maintenance of CNCC during craniofacial development.
DISCUSSION
TCDD, and derived compounds such as polychlorodibenzo-p-dioxines (PCDDs) and polychlorodibenzofurane (PCDFs), are highly toxic persistent chemicals released into the environment as un- intentional by-products of incomplete combustion of fossil fuels and wood, and during the incineration of municipal and industrial wastes. In humans, most of the exposure occurs through food, mainly meat and dairy products, fish, and shellfish. The developing fetus is especially sensitive to TCDD exposure. It is therefore important to monitor the in vivo cellular response to TCDD during development in order to understand and prevent the molecular and cellular response following exposure to dioxins.
We show here that during morphogenesis of the face, PAX3 and PAX7 regulate the environmental stress response pathway mediated by AHR signaling. Restriction of AHR signaling by PAX3 and PAX7 highlights a key function for this pathway in controlling CNCC proliferation during craniofacial development.
Interestingly, inhibition of AHR signaling only rescues the craniofacial phenotype of Pax3 Pax3-ERD/GFP mutant embryos. Severe defects in peripheral nervous system (PNS) and muscle development are maintained in the trunk of these embryos (Bajard et al., 2006; Van Ho et al., 2011) . This suggests that fundamental divergences exist between the GRNs controlling cranial and trunk NC development, possibly due to the late appearance of the head during evolution. Moreover, it points out that the regulation of AHR signaling by Pax3 may be a cranial NC-specific feature. In the trunk, Pax3 has been shown to control migration and early specification of NCC generating the PNS (Tremblay et al., 1995; Van Ho et al., 2011) . In the head, our data demonstrate that Pax3 is mainly involved in regulating the cell-cycle progression of CNCC via the regulation of AHR signaling. This probably reflects the wider range of derivatives that CNCC normally generate compared to trunk NCC. Our study has been mainly focusing on mesenchymal cells, however, analysis of cranial PNS development in Pax3 Pax3-ERD/GFP mutant embryos would further confirm or refute the divergence between trunk and cranial GRNs governing NCC development.
In addition, the study of our mouse mutants for Pax3 and Pax7 revealed that one copy of either of these two genes is sufficient to allow correct craniofacial development, demonstrating a strong functional conservation ( Figure S2B ). Interestingly, in Pax3 Pax7/Pax7 embryos, migration of NC cells is not affected (Relaix et al., 2004) . This can suggest that Pax3 and Pax7 functions are notably redundant during CNCC development or, alternatively, it can also reflect that GRNs controlling formation of the face are more robust than the ones controlling muscle development. The latter hypothesis seems more plausible when looking at the complexity of the GRNs controlling each different step of CNCC development (Betancur et al., 2010) , with several transcription factors being described to be binding to the same target gene to ensure its correct expression during the different processes of craniofacial development.
In chick and Xenopus, Pax3 and Pax7 have been described as essential factors for the induction and formation of the NC (Basch et al., 2006; Monsoro-Burq et al., 2005; Sato et al., 2005) . However, in our mouse genetic models, despite the absence of Pax3/7 or when their function is impaired, we observed normal NC induction and migration in the facial prominences of the embryo ( Figure 1C ). Whether this observation reflects a change in Pax3/7 function during evolution, and how they became associated with AHR latter during development remains an open question. Our data reveal that unlike chick and Xenopus, mouse Pax3/7 are not essential during early NC development, but are involved in late craniofacial development to control the maintenance of a cycling CNCC population. It is plausible that the association with AhR signaling, which only starts to be significantly expressed from E10.5 (Abbott et al., 1995; Jain et al., 1998) , was co-opted during evolution as a mechanism to control cell cycle of CNCC derivatives. It is believed that the AHR protein evolved about 450 million years ago (Hankinson, 1995) . Despite pre-existing natural sources of TCDD, a marked increase in environmental TCDD release occurred in the 19 th century and still persist today due to anthropogenic causes (Weber et al., 2008) . Thus, it is tempting to speculate that AHR signaling has acquired different functions during evolution. The ability of AHR to bind TCDD has made it a crucial regulator of pollutioninduced teratogenesis.
In the facial prominences of the developing mouse embryo, Ahr expression is detected from E10.5 (Abbott et al., 1995; Jain et al., 1998) , suggesting a potential role during early craniofacial development. Yet, Ahr-null mouse mutants that are non-sensitive to TCDD exposure (Fernandez-Salguero et al., 1996; Mimura et al., 1997) do not show craniofacial defects, but present defects in liver and immune system development (Fernandez-Salguero et al., 1995) . Moreover, AhR is involved in the maintenance of hematopoeitic stem cells quiescence (Singh et al., 2011) . Studies demonstrating the teratogenic effect of TCDD on mouse palate development (Abbott et al., 1994 (Abbott et al., , 1998 (Abbott et al., , 1999b Courtney and Moore, 1971; Moore et al., 1973; Pratt et al., 1984; Yamada et al., 2006; Yonemoto, 2000) are consistent with our observation that AHR signaling upregulation is associated with the occurrence of craniofacial defects. During normal development, it was shown that AHR is involved during secondary palate development and is controlled by the retinoic acid (RA) signaling pathway (Jacobs et al., 2011) . Mutant mice missing components of the RA signaling downregulate Ahr expression and do not present with secondary palate clefts when exposed to TCDD (Jacobs et al., 2011) . Additional studies performed in zebrafish reported that TCDD-induced craniofacial defects are mediated by AHR signaling. However, the defects are uniquely found in the lower jaw, affecting the structure of the mandible and the development of the Meckel's cartilage (Keller et al., 2008; Planchart and Mattingly, 2010) , highlighting possible evolutionary divergences between zebrafish and mammals.
TCDD-mediated activation of AHR signaling in a Pax3-null context is sufficient to trigger craniofacial defects, confirming a tight regulatory interaction between PAX3/7 function and AHR signaling to control growth of facial prominences in mouse. Accordingly, it was shown that AHR directly binds the first intron of p21 in vitro (Barnes-Ellerbe et al., 2004; Dere et al., 2011; Lo and Matthews, 2012) . Importantly, despite p21 expression being upregulated, all TCDD-treated Pax3 GFP/+ embryos developed normally, suggesting that additional GRNs downstream of PAX3 are also regulating craniofacial development. This will be investigated in future studies.
Altogether, our data show that during craniofacial development, Pax3 and Pax7 regulate AHR signaling expression and activity. Restriction of AHR signaling by Pax3 and Pax7 highlights a previously unknown key function for this pathway in controlling CNCC proliferation during craniofacial development.
EXPERIMENTAL PROCEDURES
Mutant Mice for Pax3 and Pax7 and Reagents
The mutant alleles for Pax3 (Pax3 nLacZ , Pax3 GFP , and Pax3 Pax3-ERD ) and for Pax7 (Pax7 LacZ ) have been described previously (Bajard et al., 2006; Mansouri et al., 1996; Relaix et al., 2003 Relaix et al., , 2005 . Of note, the Pax3 Pax3-ERD allele is a conditional one that drives the expression of the dominant-negative form of Pax3 (Pax3-ERD) composed of the Pax3 DNA binding domain fused to the engrailed repressor domain (ERD) upon activation of a Cre recombinase. In this study, the Cre was driven by the zygote specific PGK enhancer (Lallemand et al., 1998) . a-naphthoflavone and b-naphthoflavone (Sigma-Aldrich) were dissolved in DMSO then diluted in 1% carboxymethylcellulose (Sigma-Aldrich). a-naphthoflavone (7.5 milligram per kilogram (mg/kg/day) and b-naphthoflavone (30 mg/kg/day) were then administered daily, orally to pregnant female mice from E8.5 until E11.5. TCDD dissolved in toluene (Sigma-Aldrich) was diluted in corn oil (Sigma-Aldrich). TCDD (4 mg/kg/day) was then injected intra-peritoneally, to pregnant female mice from E8.5 until E11.5. All experiments were conducted according to the Institutional Animal Care and Use Committee of Paris 6 University.
Immunofluorescence and Quantification
Mouse embryos from timed pregnant females were fixed by immersion in 4% paraformaldehyde/PBS for 45 min to 2 hr at 4 C. Fixed embryos were cryoprotected by equilibration in 30% sucrose/PBS, cryosectioned, and processed for immunostaining as described in (Relaix et al., 2005) . The following primary antibodies were used, mouse anti-AHR (Abcam, 1:100), rabbit anti-AP2a (Santa Cruz, 1:200), rabbit anti-Cleaved-CASPASE-3 (Cell Signaling, 1:100), mouse anti-PAX7 (Developmental Studies Hybridoma Bank, 1:100), rabbit anti-Phospho-HISTONE-3 (Millipore, 1:500), rabbit anti-p21 (Proteintech, 1:50), and goat anti-SOX9 (R&D Systems, 1:100). Secondary antibodies DyLight 649 donkey anti-mouse IgG (H&L), DyLight 649 donkey anti-rabbit IgG (H&L), and DyLight 649 goat anti-rabbit IgG (H&L) were purchased from Jackson ImmunoResearch and Alexa 594 goat anti-mouse IgG (H&L), Alexa 594 donkey anti-goat IgG (H&L), and Alexa 594 goat anti-rabbit IgG (H&L) from Life Technologies. Analysis was carried out using a Leica TCS SPE confocal microscope and images processed with Adobe Photoshop CS4 software (Adobe Systems). Cells were counted using ImageJ (version 1.46; NIH) and Cell Counter plugin (Kurt De Vos, University of Sheffield, Academic Neurology) and were used to calculate the percentage of one cell population against another. Mean ± SD was given. The single (*), double (**), and triple (***) asterisks represent p values, p < 0.05, p < 0.005, and p < 0.0001, respectively by the Mann-Whitney non-parametric statistical test. All experiments have been performed on at least three independent embryos for each condition.
Histology, X-Gal, and DAPI Staining, Skeletal Preparation, and mRNA In Situ Hybridization For histology, sections of embryos prepared as for immunofluorescence were stained with hematoxylin and eosin (Vandenberg and Sassoon, 2009 ). X-Gal staining and whole mount in situ hybridization were performed as previously reported (Van Ho et al., 2011) . For whole mount DAPI staining, protocol described by Sandell et al. (2012) was used. Briefly, E15.5 embryos were fixed for 2 hr in 4% paraformaldehyde/PBS and washed three times with PBS before incubation with 6 mg/ml DAPI in PBS overnight at 4 C. After three washes with PBS, embryos were placed under a fully automatized Nikon Ti microscope and pictures were taken every 3 mm in the z-axis to cover all the embryo thickness. The maximum projection of all the z-axis images using Fiji software revealed the fine topological details of the embryos. Staining of bones and cartilages of whole E17.5 embryos was performed as described in Depew et al. (2002) . For in situ hybridization, probes against the following mRNAs were used, Dlx2 (Genbank, BC094317), Fgf8 (kindly provided by Martin G.), Msx1 (Genbank, BC016426), and Pax9 (Genbank, BC005794). Analysis was carried out using a Leica MZ16 F stereomicroscope. Images were processed with Adobe Photoshop CS4 software (Adobe Systems). Analyses were performed on n R 3 embryos.
FACS Sorting, Cell Culture, and TCDD Treatment
For FACS-sorting, CNCC were isolated from faces of E11.5 embryos initially incubated in digestion buffer, DMEM (Life Technologies), 0.1% trypsin, and 0.1% Collagenase D (Roche), and purified via FACS Aria II based on gating of the GFP signal.
For TCDD treatment, CNCC were isolated from faces of E10.5 embryos, incubated in digestion buffer, and purified using cell strainers (100 mm then 40 mm, BD Falcon) to obtain a single cell preparation. CNCC were then cultured in DMEM/F12 (1:1) medium for 24 hr with TCDD (100 nanomolar) or carrier in a collagen-plated dish.
RNA Extraction, Microarray, and RT-qPCR RNA was extracted directly from dissected facial prominences or from FACSsorted GFP + cells from facial prominences using NucleoSpin RNA II Extract kit (Macherey-Nagel), and the quality assessed with a NanoDrop ND-1000 (Thermo Scientific). cDNA was synthesized using the Transcriptor First Strand cDNA Synthesis Kit (Roche).
Microarrays were performed using Affymetrix GeneChip MOE 130 2.0 (PartnerChip) chips containing 45,000 oligonucleotide probes (25 length of the oligonucleotide) covering the totality of the 30,000 genes of the mouse genome. Briefly, two-cycle cDNA synthesis was performed using 100 nanogram of total RNA. cDNA was then hybridized to GeneChip Mouse Genome Array. Microarray analysis was performed using GeneChip Operating Software 1.4. For statistical analysis, data from three biological replicates of each genotype were averaged then normalized using the Affymetrix Mas5.0 algorithm. Statistical analysis was performed using Bioconductor software (http://www. bioconductor.org/). Gene expression comparison between Pax3 Pax3-ERD/GFP and Pax3 GFP/+ samples was performed using a statistical Student's t test on normalized data. Microarray data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-3238.
RT-quantitative (q)PCR reactions were carried out in triplicate using the LightCycler 480 System (Roche). The expression of each gene was normalized to that of Gapdh transcripts. Results are given as mean ± SD. The single (*), double (**), and triple (***) asterisks represent the p values, p < 0.05, p < 0.005, and p < 0.0001, respectively for Student's unpaired t tests. In Figure 4C , a-naphthoflavone treated Pax3 Pax3-ERD/GFP embryos can be statistically segregated into two populations using a Ki 2 test. We compared the expression value for a given gene obtained in each a-naphthoflavone treated Pax3 Pax3-ERD/GFP embryo to the mean of the expression values for all the DMSO treated Pax3 GFP/+ embryos (control set). If there were significant differences between these two values, the embryo was classified into the population described as responsive to the a-naphthoflavone treatment, if not the embryo was associated with the non-responsive population.
The following oligonucleotides were used: 
